ERBB2 and non-small cell lung carcinoma: The frequency of newly detected ERBB2 amplifications were 25% in oesogastric adenocarcinoma (n = 6/32), 13% in salivary gland carcinoma (parotid) (n = 2/15), 12% in biliary tract cancers (n = 5/42), 5.3% in pancreatic adenocarcinomas (n = 1/19), 4.4% in breast cancers (n = 6/134), 3% in NSCLC (n = 3/101), 3% in colon cancers (n = 2/66), 2.3% in urothelial carcinomas (n = 1/44) and 1.9% in carcinomas of the head and neck (n = 2/105) (Figure 1).